- Home
- PVBC vs CHRS Comparison
PVBC vs CHRS Comparison
Compare PVBC & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PVBC
- CHRS
- Stock Information
- Founded
- PVBC 1913
- CHRS 2010
- Country
- PVBC United States
- CHRS United States
- Employees
- PVBC N/A
- CHRS N/A
- Industry
- PVBC Major Banks
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PVBC Finance
- CHRS Health Care
- Exchange
- PVBC Nasdaq
- CHRS Nasdaq
- Market Cap
- PVBC 192.7M
- CHRS 191.3M
- IPO Year
- PVBC 2015
- CHRS 2014
- Fundamental
- Price
- PVBC $10.87
- CHRS $1.39
- Analyst Decision
- PVBC Hold
- CHRS Strong Buy
- Analyst Count
- PVBC 1
- CHRS 4
- Target Price
- PVBC $12.00
- CHRS $5.38
- AVG Volume (30 Days)
- PVBC 30.3K
- CHRS 2.0M
- Earning Date
- PVBC 01-31-2025
- CHRS 03-12-2025
- Dividend Yield
- PVBC N/A
- CHRS N/A
- EPS Growth
- PVBC N/A
- CHRS N/A
- EPS
- PVBC 0.32
- CHRS N/A
- Revenue
- PVBC $55,219,000.00
- CHRS $304,340,000.00
- Revenue This Year
- PVBC N/A
- CHRS $2.47
- Revenue Next Year
- PVBC $5.90
- CHRS N/A
- P/E Ratio
- PVBC $34.15
- CHRS N/A
- Revenue Growth
- PVBC N/A
- CHRS 44.19
- 52 Week Low
- PVBC $7.36
- CHRS $0.66
- 52 Week High
- PVBC $12.32
- CHRS $2.97
- Technical
- Relative Strength Index (RSI)
- PVBC 43.85
- CHRS 45.86
- Support Level
- PVBC $10.51
- CHRS $1.38
- Resistance Level
- PVBC $11.33
- CHRS $1.60
- Average True Range (ATR)
- PVBC 0.24
- CHRS 0.13
- MACD
- PVBC -0.04
- CHRS -0.03
- Stochastic Oscillator
- PVBC 30.51
- CHRS 9.52
About PVBC Provident Bancorp Inc. (MD)
Provident Bancorp Inc provides a range of banking products and services to small and medium-sized commercial customers. It attracts deposits from the general public and uses those funds to originate loans, commercial real estate, construction and land, and commercial business loans, and to invest in securities. The company lending activities include providing commercial real estate loans, multi-family residential real estate loans, commercial business loans, construction and land development loans, one-to four-family residential loans, home equity loans & lines of credit, and consumer loans.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.